SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
NEW YORK, March 13, 2018 -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 1:35 p.m. ET in New York, NY.
A live audio webcast of the presentation will be available under “Events & Presentations” in the Investors section of SELLAS’ website at www.sellaslifesciences.com/investors. A replay of the webcast will be available for up to 30 days on SELLAS’ website following the presentation.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]
David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
[email protected]
Source: SELLAS Life Sciences Group, Inc.
